Literature DB >> 29574473

Metabolic disorders in polycystic ovary syndrome.

Beata Wikiera1, Agnieszka Zubkiewicz-Kucharska1, Julita Nocoń-Bohusz1, Anna Noczyńska1.   

Abstract

Polycystic ovary syndrome (PCOS) is a complex disease. Depending on the used criteria the prevalence of PCOS ranges from 6 to 20%. It is necessary to exclude diseases leading to androgen excess. The participation of genetic and environmental factors is considered in the etiology of PCOS development. The highest rate of incidence of PCOS is assessed in girls who were born SGA and developed premature adrenarche later in life.The free androgen index (FAI) is concerned as the most sensitive marker of hyperandrogenaemia in PCOS although insulin resistance, anti-Müllerian hormone (AMH),and deficiency of vitamin D may intensify metabolic disturbances. The ultrasound criteria used in adolescent patients prefer the estimation of the ovarian volume or the ratio of ovarian stroma to total ovary, rather than the number of ovarian follicles. PCOS is connected with different metabolic disorders. Post-binding defect in signal transduction is responsible for insulin resistance. This defect results from an impaired activity of the kinase receptor. Moreover, the adipose tissue of PCOS women differs substantially from the tissue of the others according to morphology and function. The adipocytes produce lower amounts of adiponectin, which is an insulin-sensitizing agent. Dyspidemia with high triglycerides and low high density lipoprotein cholesterol concentrations is frequently noticed. Cardio-metabolic risk factors, insulin resistance, and endothelial dysfunction accompany PCOS from the very beginning. Oxidative stress plays a role as a link among systemic inflammation and dysfunction of endothelial cells and abnormal thecal cell action. The treatment efforts in PCOS depend on the patient's main problems. Modification of diet and lifestyle is the most important recommended advice to each woman independent of age and weight. © Polish Society for Pediatric Endocrinology and Diabetology.

Entities:  

Mesh:

Year:  2017        PMID: 29574473     DOI: 10.18544/PEDM-23.04.0094

Source DB:  PubMed          Journal:  Pediatr Endocrinol Diabetes Metab        ISSN: 2083-8441


  4 in total

Review 1.  Polycystic Ovary Syndrome: Insights from Preclinical Research.

Authors:  Jane F Reckelhoff; Noha M Shawky; Damian G Romero; Licy L Yanes Cardozo
Journal:  Kidney360       Date:  2022-06-17

2.  Cryptotanshinone Protects against PCOS-Induced Damage of Ovarian Tissue via Regulating Oxidative Stress, Mitochondrial Membrane Potential, Inflammation, and Apoptosis via Regulating Ferroptosis.

Authors:  Honglin Liu; Jiani Xie; Limin Fan; Yue Xia; Xia Peng; Jianhua Zhou; Xiaorong Ni
Journal:  Oxid Med Cell Longev       Date:  2022-04-04       Impact factor: 6.543

3.  25(OH)VitD and human endocrine and functional fertility parameters in women undergoing IVF/ICSI.

Authors:  Mei Tian; Suimin Zeng; Sufen Cai; Christoph Reichetzeder; Xiaoli Zhang; Chenjun Yin; Weihong Kuang; Kexin Cheng; Yao Jiang; Mingqiu Tao; Yuan Zeng; Ge Lin; Jian Li; Fei Gong; Berthold Hocher
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

Review 4.  Investigation of common risk factors between polycystic ovary syndrome and Alzheimer's disease: a narrative review.

Authors:  Nahid Sarahian; Hosna Sarvazad; Elham Sajadi; Nasrin Rahnejat; Narges Eskandari Roozbahani
Journal:  Reprod Health       Date:  2021-07-26       Impact factor: 3.223

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.